Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03535142
Other study ID # S-20170210
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 15, 2018
Est. completion date April 1, 2038

Study information

Verified date September 2023
Source Hospital of South West Jutland
Contact Mette M Lauridsen, MD PhD
Phone +4579182000
Email mette.enok.munk.lauridsen@rsyd.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective non-randomized intervention case control study on patients with a BMI > 35. The intervention group/cases (n=600) is comprised of bariatric patients who undergo bariatric surgery and the control group (n=600) of age, weight and comorbidity matched patients who choose not to undergo bariatric surgery. The overall aim is to examine prevalence of the spectrum of fatty liver disease (NAFLD) in these patients and the prognostic significance of NAFLD.


Recruitment information / eligibility

Status Recruiting
Enrollment 1200
Est. completion date April 1, 2038
Est. primary completion date June 1, 2035
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria case group: - Age > 18 years - BMI >35 kg/m2 and referred for bariatric surgery at Hospital of South West Jutland, Denmark - Able to give written informed consent. Inclusion criteria control group: - Age > 18 years - BMI >35 kg/m2 with no wish to undergo bariatric surgery. - Able to give written informed consent. Exclusion Criteria: - Active viral hepatitis - Not willing or able to consent - Contraindications to liver biopsy

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Bariatric surgery
Roux en y gastric bypass or gastric sleeve operation

Locations

Country Name City State
Denmark Hospital of Southwest Jutland Esbjerg

Sponsors (3)

Lead Sponsor Collaborator
Hospital of South West Jutland Odense University Hospital, University of Southern Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants who will die during the follow up period in case and control group Difference in mortality between cases and controls with various NAFLD severity on biopsy. 10 years follow up after inclusion
Secondary Number of participant who will experience progressive fatty liver disease in case and control group Difference NAFLD severity between case and control group after 10 years follow up. Simple steatosis is the mildest form and liver cirrhosis is the most serious manifestation:
Grade 1 steatosis
Grade 2 steatosis
Grade 3 steatosis
Non alcoholic steatohepatitis
Presence of fibrosis Kleiner grade 1-2
Presence of fibrosis Kleiner grade 3
Presence of liver cirrhosis
10 years follow up after inclusion
Secondary Change in continuous reaction time measurement after bariatric surgery Continuous reaction time measurement will measure reaction time instability and is a measure of metabolic encephalopathy. The method is a 10-minutes, computerised registration of a series of motor reaction times to an auditory stimulus, with results reported as the CRTindex (50 percentile/(90-10) percentile) as a parameter of reaction time variability. A CRT index below 1.9 i considerede abnormal a may be a sign of hepatic encephalopathy. 10 years follow up after inclusion
Secondary Change in EEG after bariatric surgery Change in mean dominant frequency(MD) on EEG spectral analysis. EEG disturbances in hepatic encephalopathy are (rated by severity)but there is no enough space here to describe it. 24 months after surgery
Secondary Change in intelligence quotient after bariatric surgery Measured by Weschlers adult intelligence scale (WAIS). An IQ if 100 i the norm. Range 50-150. 24 months efter surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05480696 - Soluble Fibre Supplementation in NAFLD Phase 1
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04671186 - Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan N/A
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Recruiting NCT05462353 - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH Phase 2
Completed NCT05006885 - ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) Phase 1
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Recruiting NCT04365855 - The Olmsted NAFLD Epidemiology Study (TONES) N/A
Recruiting NCT05618626 - Prevention of NAFLD and CVD Through Lifestyle Intervention N/A
Completed NCT03256526 - 6-week Safety and PD Study in Adults With NAFLD Phase 2
Enrolling by invitation NCT06152991 - Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy Phase 3
Completed NCT03681457 - Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects Phase 1
Completed NCT06244550 - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors N/A
Not yet recruiting NCT05120557 - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH N/A
Completed NCT03060694 - Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
Completed NCT02526732 - Hepatic Inflammation and Physical Performance in Patients With NASH N/A
Recruiting NCT01988441 - The Influence of Autophagy on Fatty Liver
Recruiting NCT01680003 - Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease Phase 2
Completed NCT01712711 - Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease Phase 2
Recruiting NCT00941642 - Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Phase 4